The Grünenthal Group and Amura Therapeutics have entered into a collaboration for the development of protease inhibitors focused on cathepsin inhibitors to treat pain and inflammation. With advanced lead compounds generated from Amura, Grünenthal will develop small molecule drugs and assume responsibility for further R&D.   Grünenthal has exclusive rights for worldwide clinical development, manufacturing and commercialization of potential products arising from the collaboration. Grünenthal i...